Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT
ANNOUNCEMENT ON THE PROGRESS OF PROTON THERAPY BUSINESS

This announcement is made by the board of directors (the "**Board**") of Concord Healthcare Group Co., Ltd. (the "**Company**") on a voluntary basis.

The Board is pleased to announce that, as of May 2026, the proton therapy center of the Company's subsidiary, Guangzhou Concord Cancer Center (hereinafter referred to as the "**Guangzhou Hospital Proton Center**") has been officially operational for 18 months, serving a total of over 880 patients and achieving a daily patient volume exceeding 100. This figure marks a new milestone in the precision radiotherapy capabilities for tumors in the South China region.

Patient services cover 31 provincial-level administrative regions across the country, as well as over 20 countries worldwide. The age range ranges from 13 months old children to 91 years old elderly people. The treatment scope covers various malignant tumors such as childhood tumors, central nervous system tumors, head and neck tumors (such as nasopharyngeal carcinoma), chest tumors (such as lung cancer, esophageal cancer), breast tumors, abdominal tumors (such as liver cancer), urinary system tumors (such as prostate cancer), and soft tissue sarcomas.

Moving forward, the Company will continue to optimize service processes and improve diagnosis and treatment efficiency, with the aim of delivering high-quality and precise proton therapy services to more oncology patients.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, May 27, 2026

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, and Mr. JIANG Wei as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors; and (iv) Ms. JIANG Li as employee Director.